Evidence map›Paper›PMID 30753368›Full record

ArticleClinical infectious diseases : an official publication of the Infectious Diseases Society of America2019

Impact of Rotavirus Vaccine Introduction in Children Less Than 2 Years of Age Presenting for Medical Care With Diarrhea in Rural Matlab, Bangladesh.

Lauren M Schwartz, K Zaman, Md Yunus, Ahasan-Ul H Basunia, Abu Syed Golam Faruque, Tahmeed Ahmed, Mustafizur Rahman, Jonathan D Sugimoto, M Elizabeth Halloran, Ali Rowhani-Rahbar and 2 more

Open access · hybridAbstract read
In one paragraph

Article in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.3field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors at 5 institutions in 3 countries.

Lauren M SchwartzDepartment of Epidemiology, School of Public Health, University of Washington, Seattle.
K ZamanInternational Centre for Diarrhoeal Disease Research, Bangladesh, Dhaka.
Md YunusInternational Centre for Diarrhoeal Disease Research, Bangladesh, Dhaka.
Ahasan-Ul H BasuniaInternational Centre for Diarrhoeal Disease Research, Bangladesh, Dhaka.
Abu Syed Golam FaruqueInternational Centre for Diarrhoeal Disease Research, Bangladesh, Dhaka.
Tahmeed AhmedInternational Centre for Diarrhoeal Disease Research, Bangladesh, Dhaka.
Mustafizur RahmanInternational Centre for Diarrhoeal Disease Research, Bangladesh, Dhaka.
Jonathan D SugimotoVaccine and Infectious Diseases Division, Fred Hutchinson Cancer Research Center, Seattle.
M Elizabeth HalloranDepartment of Epidemiology, School of Public Health, University of Washington, Seattle.
Ali Rowhani-RahbarDepartment of Epidemiology, School of Public Health, University of Washington, Seattle.
Kathleen M NeuzilCenter for Vaccine Development, University of Maryland School of Medicine, Baltimore.
John C VictorCenter for Vaccine Innovation and Access, PATH, Seattle, Washington.
International Centre for Diarrhoeal Disease Research · BDCape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa · ZAUniversity of Washington · USProgram for Appropriate Technology in Health · USUniversity of Maryland, Baltimore · US

Funding

Methods for Evaluating Vaccine EfficacyR37AI032042 · NIAID · FRED HUTCHINSON CANCER RESEARCH CENTER · PI HALLORAN, M ELIZABETH · 2010 to 2019
$5.1M
NIAID NIH HHS R37 AI032042
6 · The paper itself

Abstract

backgroundFollowing the conclusion of a human rotavirus vaccine (HRV) cluster-randomized, controlled trial (CRT) in Matlab, Bangladesh, HRV was included in Matlab's routine immunization program. We describe the population-level impact of programmatic rotavirus vaccination in Bangladesh in children <2 years of age.

methodsInterrupted time series were used to estimate the impact of HRV introduction. We used diarrheal surveillance collected between 2000 and 2014 within the 2 service delivery areas (International Centre for Diarrhoeal Disease Research, Bangladesh [icddr,b] service area [ISA] and government service area [GSA]) of the Matlab Health and Demographic Surveillance System, administered by icddr,b. Age group-specific incidence rates were calculated for both rotavirus-positive (RV+) and rotavirus-negative (RV-) diarrhea diagnoses of any severity presenting to the hospital. We used 2 models to assess the impact within each service area: Model 1 used the pre-vaccine time period in all villages (HRV- and control-only) and Model 2 combined the pre-vaccine time period and the CRT time period, using outcomes from control-only villages.

resultsBoth models demonstrated a downward trend in RV+ diarrheal incidences in the ISA villages during 3.5 years of routine HRV use, though only Model 2 was statistically significant. Significant impacts of HRV on RV+ diarrhea incidences in GSA villages were not observed in either model. Differences in population-level impacts between the 2 delivery areas may be due to the varied rotavirus vaccine coverage and presentation rates to the hospital.

conclusionsThis study provides initial evidence of the population-level impact of rotavirus vaccines in children <2 years of age in Matlab, Bangladesh. Further studies are needed of the rotavirus vaccine impact after the nationwide introduction in Bangladesh.

Indexed as

Delivery of Health CareRural HealthBangladeshChild, PreschoolDiarrheaFemaleHumansIncidenceInfantInfant, NewbornMalePublic Health SurveillanceRotavirusRotavirus InfectionsRotavirus VaccinesTime FactorsRotavirus Vaccinesimpactrotavirus vaccinetime-series

Identifiers

PMID30753368
PMCPMC6880338
OpenAlexW2914021640

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.